

miR-339-5p inhibits metastasis of non-small cell lung cancer by regulating the epithelial-to-mesenchymal transition

YUN LI^{1,2*}, XUELIN ZHANG^{1*}, ZHEN YANG¹, YANAN LI³, BAIYU HAN⁴ and LIANG AN CHEN¹

¹Department of Respiratory Medicine, Chinese People's Liberation Army (PLA) General Hospital and Chinese PLA Medical School, Beijing 100853; ²Department of Respiratory Medicine, The 309th Hospital of Chinese PLA, Beijing 100091; ³Department of Internal Medicine, Beijing Aerospace General Hospital, Beijing 100076; ⁴Department of Endocrinology and Metabolism, The 264th Hospital of PLA, Taiyuan, Shanxi 030000, P.R. China

Received November 10, 2015; Accepted May 5, 2017

DOI: 10.3892/ol.2017.7608

Abstract. Metastasis is a common event in cancer pathology, and represents the primary cause of cancer-associated mortality. Metastasis, which is the process in which cancer cells at the primary tumor site spread to a different location in the body and form a new tumor, is regulated by multiple factors and includes a number of steps and stages. In our previous study, it was demonstrated miR-339-5p inhibits cell migration and invasion *in vitro* and is associated with the tumor-node-metastasis stage and the lymph node metastasis status of non-small cell lung cancer. In the present study, expression of miR-339-5p was first determined in the tissues and peripheral blood of patients with non-small cell lung cancer (NSCLC) and in NSCLC cell lines. It was then demonstrated that miR-339-5p inhibits A549 and H1299 cell invasion. The underlying molecular events of miR-339-5p action in NSCLC were also explored. By luciferase assay and western blot analysis, B-cell CLL/lymphoma 6 (*BCL6*) was verified as the direct target gene of miR-339-5p. miR-339-5p may inhibit lung cancer cell invasion and migration by regulating the epithelial-to-mesenchymal transition via *BCL6* *in vitro*. It was also demonstrated that the relative expression of miR-339-5p in the peripheral blood is associated with cancer metastasis in patients with non-small cell lung cancer.

Introduction

Lung cancer accounts for ~14% of incident cases of all cancers, and was the most common cause of cancer-associated

mortality in the USA in 2013 (1). Metastasis is the process in which cancer cells in the primary site spread to a different location in the body and form a new tumor; this involves entry of tumor cells into circulatory systems (blood and lymph) from the original site, attachment to distant organs, cloning and angiogenesis (2). Metastasis is a common event in cancer pathology, and represents the primary cause of cancer-associated mortality. In lung cancer, metastasis is regulated by numerous factors and involves a number of steps and stages (1-3). Improved understanding of the molecular mechanisms of metastasis in lung cancer may lead to more effective clinical control of lung cancer.

MicroRNAs (miRNAs/miRs) are a class of endogenous, non-coding, single-stranded RNAs with a length of 20-25 nucleotides. By interacting with the 3'-untranslated regions (3'-UTRs) of target mRNAs, miRNAs silence protein expression post-transcriptionally in two ways: Degradation of the mRNAs, or inhibition of mRNA translation into proteins. miRNAs serve important roles in numerous cellular processes, including proliferation, differentiation and apoptosis (4-7), and in the development and progression of lung cancer (8-10).

Our previous study (11) identified that miR-339-5p was downregulated in non-small cell lung cancer (NSCLC) cells and tissue samples, and that its expression was inversely associated with tumor-node-metastasis (TNM) stage. Furthermore, its upregulation could inhibit NSCLC cell migration and invasion *in vitro*. Bioinformatics analyses also demonstrated that the B-cell CLL/lymphoma 6 (*BCL6*) and valosin-containing protein genes may be potential targets of miR-339-5p (11). The present study aimed to confirm that *BCL6* is the target gene of miR-339-5p, and that miR-339-5p represses the epithelial-to-mesenchymal transition (EMT) of NSCLC cells via *BCL6* regulation. EMTs are vital for morphogenesis during embryonic development and are also implicated in the conversion of early stage tumors into invasive malignancies (2,12). During the EMT process, epithelial tumor cells lose their expression of E-cadherin, which is an important epithelial cell-cell adhesion molecule, and begin to exhibit motility and invasiveness (12). In addition, the relative expression of miR-339-5p in peripheral blood and its association with disease progression were investigated.

Correspondence to: Professor Liang An Chen, Department of Respiratory Medicine, Chinese People's Liberation Army (PLA) General Hospital and Chinese PLA Medical School, 28 Fuxing Road, Haidian, Beijing 100853, P.R. China
E-mail: yunli_309@163.com

*Contributed equally

Key words: microRNA, metastasis, non-small cell lung cancer, B-cell CLL/lymphoma 6, epithelial-to-mesenchymal transition

Materials and methods

Cell culture. The NSCLC A549, H1299, H810, H358 and H1975 cell lines were provided by the Department of Respiratory Diseases (purchased from the American Type Culture Collection and maintained at the Chinese People's Liberation Army General Hospital, Beijing, China). These cells were grown in RPMI-1640 medium containing 10% fetal bovine serum (both from Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), in a humidified atmosphere of 95% air and 5% CO₂ at 37°C.

NSCLC tissue specimens and peripheral blood. The present study was approved by the Ethics Committee of the 309th Hospital of Chinese PLA (Beijing, China). A total of 60 surgical NSCLC tissue specimens or biopsy specimens and pairing peripheral blood samples were obtained from the 309th Hospital of Chinese PLA. The baseline clinical features of the patient are shown in Table I.

All patients signed informed consent forms. A total of 32 patients underwent complete surgical resection of the primary tumor. Following surgical resection or biopsy, the peripheral blood samples were obtained. After 6 months, the peripheral blood samples were obtained again. Patients who had received chemotherapy or radiation therapy prior to surgery, or who had rheumatic disease, acute infection, human immunodeficiency virus infection or other types of cancer, were excluded from the present study. The clinical staging was performed according to 7th American Joint Committee on Cancer/Union for International Cancer Control TNM classification (13).

Isolation of total RNA and reverse transcription (RT)-quantitative polymerase chain reaction (qPCR) analysis. RNA from the NSCLC cells and fresh tissue samples was extracted using the mirVana™ RNA Isolation kit (catalog no. AM1560; Ambion®; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. RNA from peripheral blood cells was isolated with the miRNeasy™ Mini kit (catalog no. 217004; Qiagen, Inc., Valencia, CA, USA). The RNA quality and quantity were determined by spectrophotometry (ND-1000; NanoDrop Technologies; Thermo Fisher Scientific, Inc.).

RNA samples from lung cancer cells, tissue samples or peripheral blood cells were subjected to RT reactions using the TaqMan MicroRNA Reverse Transcription kit (catalog no. 4366596; Thermo Fisher Scientific, Inc.). Primers were: miRNA-339-5p (catalog no. 4427975-ID002257) and U6, (catalog no. 4427975-ID001973) (Thermo Fisher Scientific, Inc.). The thermocycling conditions were as follows: 16°C for 30 min and 42°C for 30 min, 85°C for 5 min and 4°C for 5 min. The cDNA was then amplified by qPCR using TaqMan assays with the aforementioned primers and TaqMan Universal Master Mix (catalog no. 4440040; Thermo Fisher Scientific, Inc.) in three independent experiments according to the manufacturer's protocol. The thermocycling conditions were as follows: 50°C for 2 min and 95°C for 10 min, for 40 cycles, and each cycle contained two steps, 95°C for 15 sec, then 60°C for 60 sec). PCR was performed in triplicate for each individual sample. U6 small nuclear RNA was used as an internal

Table I. Baseline clinical features of patients.

Clinical features	Case no.
Age (years)	
≥60	41
<60	19
Gender	
Female	31
Male	29
Smoking history	
Yes	21
No	39
Pathological type	
Adenocarcinoma	41
Squamous cell carcinoma	10
Mixed type	9
Clinical stage	
I	10
II	17
III	21
IV	12
Lymph node metastases	
N0	12
N1	11
N2	7
N3	30
Distant metastases	
M0	38
M1	12

control. The miRNA expression data are presented as the fold difference relative to U6 based on the 2^{-ΔΔC_q} method (14), where ΔC_q = C_qmiRNA - C_qU6.

Transient miRNA transfection. A549 and H1299 cells (1×10⁶) were seeded and cultured overnight in 6-well plates. Subsequently, the cells were transfected with 20 pmol miR-339-5p mimic (Shanghai GenePharma Co., Ltd., Shanghai, China) or 20 pmol 2'-O methylated single-stranded miR-339-5p antisense oligonucleotides (inhibitor; Shanghai GenePharma Co., Ltd.) using Lipofectamine 2000® (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The miRNA mimics consisted of small double-stranded RNA oligonucleotides with the following sequence: positive-sense strand, 5'-UCCCUGUCCUCCAGG AGCUCACG-3'; and antisense strand, 5'-UGAGCUCCUGGA GGACAGGGAUU-3'. The inhibitor sequence was 5'-CGU GAGCUCCUGGAGGACAGGGA-3'. Negative control RNAs (Shanghai GenePharma Co., Ltd.) were used to eliminate potential nonsequence-specific effects, and the sequences used were not homologous to any sequence in the human genome. The sequences were, 5'-UUCUCCGAACGUGUCACGUTT-3' (positive-sense strand) and 5'-ACGUGACACGUUCGUAGA ATT-3' (antisense strand; a negative control for the miRNA

mimic) and 5'-CAGUACUUUUGUGUAGUACAA-3' (a negative control for the mRNA antisense transfection).

Cell invasion assay. Transwell inserts (24-well insert; pore size, 8 μ m; Corning Incorporated, Corning, NY, USA) were used to explore the effects of miR-339-5p on A549 and H1299 cell invasion *in vitro*. The inserts were initially coated with 100 μ l pre-cooled serum-free RPMI-1640 and Matrigel (1:10; BD Biosciences, Franklin Lakes, NJ, USA) and allowed to solidify at 37°C in 5% CO₂ for 3 h. Subsequently, 5x10⁴ cells were resuspended in 100 μ l serum-free RPMI-1640 and placed in the top portion of each Transwell chamber. The lower chamber was filled with RPMI-1640 medium containing 10% fetal calf serum (HyClone; GE Healthcare Life Sciences, Little Chalfont, UK) as a chemoattractant, and the plates were then incubated at 37°C in 5% CO₂ for 24 h. The cells on the upper surface of the membrane were removed using cotton swabs and PBS, and the cells on the lower surface of the insert were fixed in 75% methanol and stained with 0.1% crystal violet at room temperature for 15 min. Images of five random fields of view for each insert were captured under a light microscope at x200 magnification. The cells in the images were counted, and the data were summarized as the mean \pm standard deviation. The assays were conducted in duplicate for three independent experiments.

Plasmid construction. The *BCL6* 3'-UTR was amplified with the following primers: *BCL6*-3'-UTR-long non-coding (lnc)-up, 5'-CGGAATTCAGCATGGAGTGTGATGCTTTCGTCTCCA-3'; and *BCL6*-3'-UTR-lnc-down, 5'-GCTCTAGACAGTTTGACTTTTCAACATTTTATTCTTATA-3'. The PCR product was inserted between the *Xba*I and *Eco*RI sites, immediately downstream of the stop codon of luciferase gene in pGL3M, which was obtained from the pGL3-control vector (Promega Corporation, Madison, WI, USA) by inserting *Pst*I, *Eco*RI and *Nde*I sites (15). To introduce mutations into the seed sequences in the *BCL6* 3'-UTR, recombinant PCR was performed using the aforementioned primers and the following primers: *BCL6*-3'-UTR mutated (mut)-down, 5'-AAAGTGATCCGGAGTAGTTATAACACAAGCATGACGCAGA-3'; *BCL6*-3'-UTR mut-up, 5'-GCGTCATGCTTGTGTATTAACTACTCCGCATCACTTTTTT-3'. The mut-down and mut-up primers were respectively used with lnc-up and lnc-down primers for two PCR. Then the two products were purified and mixed. Subsequently, lnc-up and lnc-down primers were used to amplify the mixture. Finally, the mutation for the seed sequence was gained.

Luciferase reporter assay. pGL3-*BCL6* 3'-UTR and pGL3-*BCL6* 3'-UTR-mut were co-transfected with 20 pmol miRNA-339-5p mimics or negative controls into A549 and H1299 cells using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). Luciferase assay (Promega Corporation) was performed by detecting firefly luciferase activity with normalizing to *Renilla* luciferase activity after 48 h of transfection as previous study (16). All experiments were performed in triplicate and repeated three times.

Western blot analysis. Following transfection of the cells with miR-339-5P mimics, inhibitors or controls, western

blot analyses were performed, as previously described (15), to detect the levels of BCL6, as well as the EMT-associated markers neural (N)-cadherin and epithelial (E)-cadherin, using GAPDH as the loading control. The primary antibodies were BCL-6 (D-8; catalog no. sc-7388), GAPDH (0411; catalog no. sc-47724) and NFkBp65 (C-20; catalog no. sc-372) (all from Santa Cruz Biotechnology, Inc., Dallas, TX, USA). Each experiment was repeated three times.

Recovery of *BCL6* expression. The expression vector for the *BCL6* gene was generated by cloning the PCR product into a pGL3M vector using the following primers: 5'-CGGAATTCAGGCATTGGACTCAAGATGG-3'; and 5'-GCTCTAGAAACAAAAACATTCCCCCACA-3'. For transfection, cells were seeded in 6-well plates and then transfected with the indicated plasmids using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol.

Statistical analysis. All statistical analyses were performed using SPSS v13.0 (SPSS, Inc., Chicago, IL, USA). Differences between variables were assessed by Student's t-test. A Spearman's correlation analysis was used to determine the correlation between miR-339-5p expression levels in the tissues and in the paired peripheral blood samples. P<0.05 was considered to indicate a statistically significant difference.

Results

miR-339-5p expression in NSCLC cells and patients with NSCLC. To verify the expression of miR-339-5p in NSCLC, five typical NSCLC cell lines were used. As demonstrated in Fig. 1A, miR-339-5p was expressed in all of the cells, and its expression was highest in A549 cells and lowest in H1299 cells; these two cells lines were then used for further study.

The levels of miR-339-5p were also measured in the peripheral blood samples of 60 patients at the time of their admission to hospital and 6 months later, in order to determine the association between the expression of miR-339-5p in peripheral blood cells and NSCLC metastasis. Spearman's correlation analysis demonstrated that miR-339-5p levels in peripheral blood samples were positively correlated to the levels in tumor tissues (r=0.932; Fig. 1B), indicating that peripheral miR-339-5p was a good marker for additional study. At 6 months after admission, the peripheral miR-339-5p expression levels in the patients (n=27) with non-new metastatic cancer was not significantly different from that at the time of admission (P>0.05; Fig. 1C). Conversely, peripheral miR-339-5p expression in the patients (n=33) with new metastatic cancer was increased significantly after 6 months (P<0.05; Fig. 1D) compared with that at the time of hospital admission.

miR-339-5p inhibits A549 and H1299 cell invasion. A gain-of-function assay was adopted in A549 and H1299 cell lines to reveal the effect of miR-339-5p on invasion, by transfecting miR-339-5p mimics into the two cell lines. RT-qPCR confirmed a significant increase in the expression of miR-339-5p in cells transfected with the mimic compared with cells transfected with the negative control, and this increase was concomitant with a significant decrease in the number of




Figure 1. Expression of miR-339-5p in five NSCLC cell lines and in patients with NSCLC. (A) Relative expression of miR-339-5p in the NSCLC cell lines A549, H1299, H810, H358 and H1975 (the relative expression of A549 is the reference). (B) miR-339-5p expression levels (ΔCt) were determined to be positively correlated ($r=0.932$) between cancer tissues and peripheral blood samples in patients with NSCLC, as assessed by Spearman's rank correlation analysis. (C and D) Peripheral miR-339-5p expression (ΔCt) levels were determined at different time points relative to treatment (0 represents the time of first obtaining tissue samples) of patients with (C) non-metastatic cancer ($n=27$) and (D) metastatic cancer ($n=33$) (* $P<0.05$; ns, not significant). miR, microRNA; NSCLC, non-small cell lung cancer.




Figure 2. Inhibition of cell invasion by miR-339-5p in non-small cell lung cancer cells. A549 or H1299 cells were transfected with (A and B) miR-339-5p mimics or (C and D) miR-339-5p inhibitors, or their respective controls. Cell invasion was evaluated using Matrigel-coated Transwell chambers, and invaded cells were fixed and stained with 0.1% crystal violet. (A and C) Representative images of the invaded cells are shown (scale bar; 100 μ m). (B and D) Histograms demonstrate the miR-339-5p mRNA expression levels in the transfected cells (left), and the corresponding relative cell invasion (right); * $P<0.05$ vs. control (vector or scramble). (A and B) Following transfection with mimics and vector (mimics control), the expression of microRNA339-5p of A549 and H1299 increased 7 and 6 times respectively, so the number of migrating cells decreased (198 ± 5 vs. 56 ± 4 , 230 ± 3 vs. 53 ± 2 , $P<0.05$). (C and D) Following transfection with inhibitor and scramble (inhibitor control), the expression of microRNA339-5p of A549 decreased 2.8 times, so the number of migrating cells increased (95 ± 3 vs. 210 ± 2 , $P<0.05$). All values presented are the mean \pm standard deviation of triplicate measurements. Experiments were repeated three times. This is one of the results. miR, microRNA.




Figure 3. Inhibition of *BCL6* expression by miR-339-5p in A549 and H1299 cells. (A) Wild-type and Mut forms of putative miR-339-5p target sequences (bold font) in the *BCL6* 3'-UTR. The underlined sequence indicates the mutated sequence. (B) Results were shown as the relative luciferase activity (\pm standard deviation) compared with the negative control (transfected with empty vector only) in either A549 or H1299 cells. (C) Western blot analysis of A549 and H1299 cells transfected with (a) miR-339-5p mimics or (b) miR-339-5p inhibitors. The histograms on the right demonstrate the corresponding miR-339-5p relative expression levels compared with the control (transfected with vector) in either A549 or H1299 cells for three independent experiments. All values presented are the mean \pm standard deviation of triplicate measurements. Experiments were repeated three times. *P<0.01. Experiments were repeated three times and one result is shown. miR, microRNA; *BCL6*, B-cell CLL/lymphoma 6; UTR, untranslated region; Mut, mutated.

invading cells (P<0.01; Fig. 2A and B). For the loss-of-function assay, an inhibitor of miR-339-5p was transfected into A549 cells. Subsequently, the expression of miR-339-5p was significantly decreased, and this was concomitant with a significant increase in the number of invading cells, as compared with cells transfected with the scramble control (P<0.01; Fig. 2C and D). These results indicate that miR-339-5p has an inhibitory effect on cell invasion.

miR-339-5p inhibits *BCL6* expression by targeting its 3'-UTR. In our previous study, target prediction programs, TargetScan and miRanda, determined that *BCL6* was a potential target gene

of miR-339-5p (11). To confirm this, Dual-Luciferase assays were performed in A549 and H1299 cell lines transfected with reporter vectors containing the wild-type or mutated forms of the *BCL6* 3'-UTR (Fig. 3A). The results demonstrated that transfection with miR-339-5p mimics decreased the luciferase activity in A549 and H1299 cells transfected with reporter vector containing the wild-type *BCL6* 3'-UTR, whereas miR-339-5p did not affect the luciferase activity in cells when the *BCL6* 3'-UTR was mutated (Fig. 3B). Western blot analysis demonstrated that miR-339-5p mimic transfection inhibited *BCL6* expression in A549 and H1299 cells compared with the controls (Fig. 3C-a). By contrast, transfection with the miR-339-5p inhibitor increased *BCL6* levels in A549 cells (Fig. 3C-b). These results suggest that miR-339-5p inhibits *BCL6* expression by directly targeting its 3'-UTR in NSCLC cells.

miR-339-5p regulates the EMT by inhibiting *BCL6*. The EMT is one of the most important mechanisms underlying the metastatic ability of cancer cells. To determine whether miR-339-5p inhibited NSCLC cells from migrating and invading via regulation of EMT, the effects of miR-339-5p on EMT-associated markers were examined in A549 cells. The overexpression of miR-339-5p significantly inhibited the expression levels of *BCL6* and the mesenchymal marker N-cadherin, while increasing the expression of the epithelial marker E-cadherin. In addition, recovery of *BCL6* expression in miR-339-5p-overexpressing cells could attenuate the effects of miR-339-5p overexpression on the regulation of EMT markers (Fig. 4A). Concordantly, downregulation of miR-339-5p by transfection with the miR-339-5p inhibitor led to increased levels of *BCL6* and N-cadherin, and decreased levels of E-cadherin (Fig. 4B). These results suggest that miR-339-5p may regulate EMT, and that *BCL6* is essential in this process. To verify this, miR-339-5p was overexpressed in cells in which *BCL6* was knocked down, revealing that miR-339-5p overexpression failed to affect the levels of EMT markers when *BCL6* was knocked down (Fig. 4C). Therefore, it was concluded that miR-339-5p regulates EMT via *BCL6*.

Discussion

Previously, multiple studies have demonstrated that miRNAs are associated with cancer metastasis. The molecular mechanisms underlying this association may involve various aspects, as follows.

Firstly, miRNAs can regulate the metastasis of cancer cells by regulating the expression of oncogenes or tumor suppressor genes. Asangani *et al* (17) identified that miR-21 stimulated invasion and migration in colon cancer cells by inhibiting programmed cell death protein 4, which has been confirmed to be tumor suppressor gene. Additionally, Bourguignon *et al* (18) verified this result in breast cancer cells. Furthermore, a study by Li *et al* (19) demonstrated that miR-34a inhibited cell migration and invasion by the down-regulation of proto-oncogene C-met expression in human hepatocellular carcinoma cells.

Secondly, miRNAs can regulate metastasis by regulating the expression of tumor metastasis-associated genes, such as sex-determining region Y-box 4, radixin (*RDX*) and Ras




Figure 4. miR-339-5p regulates the epithelial-mesenchymal transition by inhibiting BCL6. Western blot analyses were performed on A549 cells. A549 cells transfected with (A) miR-339-5p mimics, miR-339-5p mimics plus BCL6, (B) miR-339-5p inhibitor, (C) BCL6 siRNA, or miR-339-5p mimics plus BCL6 siRNA, were cultured in regular medium. miR, microRNA; BCL6, B-cell CLL/lymphoma 6; siRNA, small interfering RNA; N-cadherin, neural cadherin; E-cadherin, epithelial cadherin.

homolog family member A (*RHOA*). In breast cancer cells, miR-31 inhibited cell invasion and migration by inhibiting Frizzled class receptor 3, integrin subunit α 5, matrix metalloproteinase 16, *RDX* and *RHOA* genes, which may promote metastasis (20). Furthermore, miR-373 and miR-520c, which are downregulated in prostate cancer cells and tumors isolated from prostatectomy compared with in their benign counterparts, may suppress cluster of differentiation 44 translation and enhance the invasion of cancer cells *in vitro* (21).

Thirdly, miRNAs may regulate metastasis by regulating the angiogenesis of tumor cells. Tumor growth depends on the formation of new blood vessels to facilitate blood perfusion throughout tumor tissues. A previous study showed that the downregulation of miR-130a caused the overexpression of the Homeobox A5 protein, which downregulated the expression of the angiogenesis-promoting factors vascular endothelial growth factor receptor and hypoxia-inducible factor-1, resulting in the inhibition of tumor metastasis (22,23).

Fourthly, miRNAs may regulate metastasis by inhibiting DNA methylation-associated enzymes, which alter the DNA methylation status of tumor cells. Fabbri *et al* (24) revealed that the miR-29 family reverted aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and B.

Finally, miRNAs may regulate metastasis via the regulation of EMT. EMT involves the alteration from an epithelial to a fibroblast or mesenchymal cell phenotype, with cells gaining migratory ability. Numerous studies have demonstrated that EMT is important for the progress of tumor metastasis, and various miRNAs are involved in EMT regulation (25-28). The miR-200 family (which includes miR-200a, miR-200b, miR-200c, miR-141 and miR-429) are important regulators of EMT. Studies have identified that the miR-200 family could inhibit EMT and cancer cell migration by directly targeting E-cadherin transcriptional repressors, including zinc finger E-box-binding homeobox (ZEB)1, ZEB2, (also known as SIP1) and transcription factor 8 (29-31).

Our previous study suggested that miR-339-5p inhibited NSCLC cell migration and invasion; in patients with NSCLC, the expression of miR-339-5p was decreased in cancer tissues compared with normal lung tissues. Furthermore, statistical analysis demonstrated that miR-339-5p expression was inversely correlated with TNM stage and lymph node metastasis (11). In the present study, *BCL6* was verified as the direct

target gene of miR-339-5p, and miR-339-5p was shown to regulate EMT through BCL6.

BCL6 is a 95-kDa nuclear protein, which is encoded by a gene located on chromosome 3q27 and acts as transcriptional repressor; it was originally characterized as a regulator of B-lymphocyte growth and development. BCL6 has been implicated in the development and growth of B-cell lymphoma (32-35). Previously, numerous studies have demonstrated that *BCL6* is associated with cancer metastasis. In breast cancer cell lines, Wu *et al* (36) suggested that miR-339-5p may inhibit the expression of *BCL6* mRNA, which was associated with suppressed migration and invasion of cells. Zhao *et al* (37) identified that the downregulation of miR-127 expression may promote metastasis and proliferation, and that *BCL6* was a target of miR-127. Pinto *et al* (38) demonstrated that, in metastatic lymph nodes, the expression of BCL6 protein was significantly lower compared with that in the corresponding primary breast cancer. Hirata *et al* (39) revealed that maintenance of BCL6 function was important for the regulation of progression in gastric cancer. In the present study, *BCL6* was confirmed to be a target gene of miR-339-5p and was demonstrated to regulate the invasiveness of NSCLC cells *in vitro*. Additionally, it was verified that the relative expression of peripheral miR-339-5p increases in patients with metastatic NSCLC.

In conclusion, the present study provides evidence that miR-339-5p may inhibit lung cancer cell invasion and migration by regulating EMT through BCL6 *in vitro*, and that miR-339-5p expression is associated with cancer metastasis, indicating that miR-339-5p may be an important biomarker for lung cancer metastasis.

References

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. *CA Cancer J Clin* 64: 9-29, 2014.
2. Steeg PS: Tumor metastasis: Mechanistic insights and clinical challenges. *Nat Med* 12: 895-904, 2006.
3. Fidler IJ: The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. *Nat Rev Cancer* 3: 453-458, 2003.
4. Croce CM and Calin GA: miRNAs, cancer, and stem cell division. *Cell* 122: 6-7, 2005.
5. Iorio MV and Croce CM: MicroRNAs in cancer: Small molecules with a huge impact. *J Clin Oncol* 27: 5848-5856, 2009.
6. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. *Cell* 116: 281-297, 2004.

7. Mendell JT: MicroRNAs: Critical regulators of development, cellular physiology and malignancy. *Cell Cycle* 4: 1179-1184, 2005.
8. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, *et al*: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. *Cancer Cell* 9: 189-198, 2006.
9. Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemliadis A and Kurie JM: Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. *Genes Dev* 23: 2140-2151, 2009.
10. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M and Allgayer H: Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. *Mol Cancer Res* 8: 1207-1216, 2010.
11. Li Y, Zhao W, Bao P, Li C, Ma XQ, Li Y and Chen LA: miR-339-5p inhibits cell migration and invasion *in vitro* and may be associated with the tumor-node-metastasis staging and lymph node metastasis of non-small cell lung cancer. *Oncology Lett* 8: 719-725, 2014.
12. Kang Y and Massagué J: Epithelial-mesenchymal transitions: Twist in development and metastasis. *Cell* 118: 277-279, 2004.
13. Sobin LH, Gospodowicz MK and Wittekind C (eds): International Union against Cancer: TNM Classification of Malignant Tumours. 7th edition. Wiley-Blackwell, New York, NY, 2011.
14. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
15. Zhang X, Zhu J, Xing R, Tie Y, Fu H, Zheng X and Yu B: miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. *Lung Cancer* 77: 488-494, 2012.
16. Fan Z, Cui H, Xu X, Lin Z, Zhang X, Kang L, Han B, Meng J, Yan Z, Yan X and Jiao S: miR-125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting STAT3. *Oncotarget* 6: 25266-25280, 2015.
17. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S and Allgayer H: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. *Oncogene* 27: 2128-2136, 2008.
18. Bourguignon LY, Spevak CC, Wong G, Xia W and Gilad E: Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-2, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. *J Biol Chem* 284: 26533-26546, 2009.
19. Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y and Zheng X: miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. *Cancer Lett* 275: 44-53, 2009.
20. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, Brock JE, Richardson AL and Weinberg RA: A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. *Cell* 137: 1032-1046, 2009.
21. Yang K, Handorean AM and Iczkowski KA: MicroRNAs 373 and 520c are downregulated in prostate cancer, suppress CD44 translation and enhance invasion of prostate cancer cells *in vitro*. *Int J Clin Exp Pathol* 2: 361-369, 2009.
22. Rhoads K, Arderiu G, Charboneau A, Hansen SL, Hoffman W and Boudreau N: A role for Hox A5 in regulating angiogenesis and vascular patterning. *Lymphat Res Biol* 3: 240-252, 2005.
23. Chen Y and Gorski DH: Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. *Blood* 111: 1217-1226, 2008.
24. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, *et al*: MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. *Proc Natl Acad Sci USA* 104: 15805-15810, 2007.
25. Bracken CP, Gregory PA, Khew-Goodall Y and Goodall GJ: The role of microRNAs in metastasis and epithelial-mesenchymal transition. *Cell Mol Life Sci* 66: 1682-1699, 2009.
26. Gregory PA, Bracken CP, Bert AG and Goodall GJ: MicroRNAs as regulators of epithelial-mesenchymal transition. *Cell Cycle* 7: 3112-3118, 2008.
27. Polyak K and Weinberg RA: Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. *Nat Rev Cancer* 9: 265-273, 2009.
28. Ma L and Weinberg RA: Micromanagers of malignancy: Role of microRNAs in regulating metastasis. *Trends Genet* 24: 448-456, 2008.
29. Park SM, Gaur AB, Lengvel E and Peter ME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. *Genes Dev* 22: 894-907, 2008.
30. Hurteau GJ, Carlson JA, Spivack SD and Brock GJ: Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. *Cancer Res* 67: 7972-7976, 2007.
31. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. *Nat Cell Biol* 10: 593-601, 2008.
32. Chang CC, Ye BH, Chaganti RS and Dalla-Favera R: BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. *Proc Natl Acad Sci USA* 93: 6947-6952, 1996.
33. Polo JM, Dell'Oso T, Ranuncolo SM, Cerchiotti L, Beck D, Da Silva GF, Prive GG, Licht JD and Melnick A: Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. *Nat Med* 10: 1329-1335, 2004.
34. Phan RT, Saito M, Basso K, Niu H and Dalla-Favera R: BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. *Nat Immunol* 6: 1054-1060, 2005.
35. Jardin F, Ruminy P, Bastard C and Tilly H: The BCL6 proto-oncogene: A leading role during germinal center development and lymphomagenesis. *Pathol Biol (Paris)* 55: 73-83, 2007.
36. Wu ZS, Wu Q, Wang CQ, Wang XN, Wang Y, Zhao JJ, Mao SS, Zhang GH, Zhang N and Xu XC: miR-339-5p inhibits breast cancer cell migration and invasion *in vitro* and may be a potential biomarker for breast cancer prognosis. *BMC Cancer* 10: 542, 2010.
37. Zhao X, Duan Z, Liu X, Wang B, Wang X, He J, Yao Z and Yang J: MicroRNA-127 is downregulated by Tudor-SN protein and contributes to metastasis and proliferation in breast cancer cell line MDA-MB-231. *Anat Rec (Hoboken)* 296: 1842-1849, 2013.
38. Pinto AE, André S, Silva G, Vieira S, Santos AC, Dias S and Soares J: BCL-6 oncoprotein in breast cancer: Loss of expression in disease progression. *Pathobiology* 76: 235-242, 2009.
39. Hirata Y, Ogasawara N, Sasaki M, Mizushima T, Shimura T, Mizoshita T, Mori Y, Kubota E, Wada T, Tanida S, *et al*: BCL6 degradation caused by the interaction with the C-terminus of pro-HB-EGF induces cyclin D2 expression in gastric cancers. *Br J Cancer* 100: 1320-1329, 2009.